In ex-vivo treated malignant ascites-derived BC-3 cells, an important variation in transcript level was noted with single agent treatment with either arsenic or IFN (p<0.001) except for LANA-1 transcript with IFN (Figure 5A). The gene discussed is IFNA1; the disease is breast cancer.